RBC keeps USD 110.00 target for Zimmer Biomet stock

Published on 10/05/2026 at 09:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 2.18 billion in the second quarter, up 4.80 percent. Zimmer Biomet stock costs EUR 78.95 on October 5, 2026 after EUR 78.46.

Isometrische Wertschöpfungskette von Rohmaterial bis chirurgischer Implantation — Zimmer Biomet US98956P1021 illustriert isometrische Wertschöpfungskette von Rohmaterial bis chirurgischer Implantation im Operationssaal, Illustration mit AI erstellt.

Zimmer Biomet stock (ISIN US98956P1021) was trading at EUR 78.95 at Lang & Schwarz on October 5, 2026 at 9:29 a.m. CEST, up 0.62 percent versus the prior close of EUR 78.46. The latest analyst signal is constructive: according to Markets Insider on October 2, 2026, RBC Capital maintained its Buy rating and USD 110.00 price target, based on a report dated October 1, 2026.

Second-quarter growth supports the target

Yahoo Finance reported that Zimmer Biomet generated USD 2.177 billion in net sales in the second quarter of 2026, representing 4.80 percent reported growth from the same quarter a year earlier. GAAP diluted earnings per share reached USD 1.03, compared with USD 0.77 in the second quarter of 2025.

The operating picture was mixed beneath the revenue increase. Yahoo Finance reported adjusted operating margin of 25.70 percent in the second quarter, down 210 basis points year over year, while operating cash flow reached USD 447.8 million and free cash flow totaled USD 308.0 million.

Guidance points to measured acceleration

Management raised full-year 2026 organic constant currency revenue growth guidance to 2.25-3.25 percent from 1.00-3.00 percent, according to Yahoo Finance's transcript of the August 5, 2026 earnings call. Adjusted earnings per share guidance also increased to USD 8.47-8.59 from USD 8.40-8.55.

The guidance improvement gives the RBC target a fundamental reference, but execution remains central to the case. Zimmer Biomet said its U.S. commercial transition was progressing, while pricing was an 80-basis-point headwind in the second quarter and full-year operating margin was expected to decline by more than 50 basis points.

Next report date is November 4

Nasdaq lists November 4, 2026 as the estimated next earnings date and cites a consensus earnings-per-share forecast of USD 1.89 for the quarter. That date puts the next test of the raised outlook ahead of investors, with the prior-year comparison at USD 1.90.

Stock trades above the prior close

Zimmer Biomet was trading at EUR 78.95 at Lang & Schwarz on October 5, 2026 at 9:29 a.m. CEST, plus 0.62 percent versus the Lang & Schwarz prior close of EUR 78.46. The further course of trading is shown by the continuously updated real-time quote of Zimmer Biomet stock.